# US 2023/0058368 A1 · Therapeutic applications of artificial cerebrospinal fluid and tools provided therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058368 A1
- Document ID: US20230058368A1
- Status: Published application
- Kind: A1
- Application number: 17/980,094
- Filed: 2022-11-03
- Published: 2023-02-23
- Earliest claimed: 2014-10-15
- Assignees: P&X Medical NV
- Applicants: P&X Medical NV
- Inventors: Peter Wostyn
- Web page: https://patentgrep.com/patent/US20230058368A1

## CPC

- A61M 27/006: {Cerebrospinal drainage; Accessories therefor, e.g. valves}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61M 5/142: Pressure infusion, e.g. using pumps
- A61M 5/14276: {specially adapted for implantation}
- A61M 5/172: electrical or electronic
- A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- G16H 20/17: delivered via infusion or injection
- A61M 2202/0464: Cerebrospinal fluid
- A61M 2230/005: Parameter used as control input for the apparatus
- G16H 40/63: for local operation
- G16H 40/67: for remote operation
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Described herein is the use of CSF, more particularly external CSF or CSF-like compositions for the treatment and prevention of different diseases. More particularly, the application provides for the administration of CSF to the intrathecal space or the cerebral ventricles of a patient to increase intracranial pressure and/or CSF flow.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A method of treating Alzheimer's Disease in a patient in need thereof, said method comprising administering to said patient cerebrospinal fluid (CSF) or artificial CSF in an amount effective to increase the rate of CSF turnover and clearance.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the CSF or artificial CSF is administered into an intrathecal space or a cerebral ventricle of said patient.

### Claim 28 (depends on 26)

The method of claim 26, wherein the CSF or artificial CSF is administered to the patient using a pump that is controlled by a microcontroller that activates the pump in response to a pressure sensor that monitors the patient's CSF pressure or intracranial pressure (ICP), wherein the pump is an implantable pump or an external pump.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the CSF or artificial CSF is administered by an apparatus for infusing fluid into a body cavity, the apparatus comprising:
the pump;
a reservoir containing CSF or artificial CSF;
an infusion catheter having an inlet end coupled to the reservoir, and an outlet end coupled to the pump; and
an inflow catheter having an outlet end configured to be disposed in fluid communication with a body cavity, and an inlet end coupled to the pump,
wherein the pump is configured to selectively move CSF or artificial CSF from the reservoir through the infusion catheter and the inflow catheter to the body cavity at a rate and volume sufficient to increase the rate of CSF turnover and clearance.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the pressure sensor is disposed in communication with the inflow catheter to monitor pressure of the CSF.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the microcontroller includes a clock, and further is programmed to activate the pump periodically responsive to the clock to pump a predetermined amount of CSF or artificial CSF from the reservoir to the body cavity.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the outlet end of the inflow catheter comprises a flange configured to promote sealing of the brain of the patient where the outlet catheter passes therethrough.

### Claim 33 (depends on 29)

The method according to claim 29, wherein said apparatus further comprises:
a battery coupled to the pump; and
an inductive charging circuit coupled to the battery.

### Claim 34 (depends on 33)

The method according to claim 33, wherein said apparatus further comprises an extracorporeal controller, the extracorporeal controller including an inductive energy transmission circuit configured to transmit energy to the inductive charging circuit.

### Claim 35 (depends on 34)

The method of claim 34, wherein the microcontroller is coupled to a first transceiver and the extracorporeal controller is coupled to a second transceiver, and the first and second transceiver communicate information relating to operation of the pump.

### Claim 36 (depends on 34)

The method according to claim 34, wherein the microcontroller receives programmed instructions from the extracorporeal controller relating to pump activation intervals and targeted volumes of CSF or artificial CSF to be pumped.

### Claim 37 (depends on 34)

The method of claim 34, wherein the extracorporeal controller receives data from the microcontroller relating to pump activation periods, measured pressures, and actual volumes of CSF or artificial CSF pumped through the inflow catheter.

### Claim 38 (depends on 29)

The method according to claim 29, wherein said apparatus further comprises a one-way valve disposed between the reservoir and the outlet end of the inflow catheter, the one-way valve configured to permit CSF or artificial CSF to flow only from the infusion catheter to the inflow catheter.

### Claim 39 (depends on 29)

The method according to claim 29, wherein the reservoir is adapted to be implanted within the patient.

### Claim 40 (depends on 26)

The method according to claim 26, wherein the artificial CSF comprises sodium ions at a concentration of 140-190 mM, potassium ions at a concentration of 2.5-4.5 mM, calcium ions at a concentration of 1-1.5 mM, magnesium ions at a concentration of 0.5-1.5 mM, phosphor ions at a concentration of 0.5-1.5 mM, and chloride ions at a concentration of 100-200 mM.

### Claim 41 (depends on 26)

The method according to claim 26, wherein the artificial CSF comprises one or more therapeutic agents.
